Cargando…
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the phar...
Autores principales: | Qian, Hong-jie, Wang, Yu, Zhang, Meng-qi, Xie, Yuan-chao, Wu, Qing-qing, Liang, Li-yu, Cao, Ye, Duan, Hua-qing, Tian, Guang-hui, Ma, Juan, Zhang, Zhuo-bing, Li, Ning, Jia, Jing-ying, Zhang, Jing, Aisa, Haji Akber, Shen, Jing-shan, Yu, Chen, Jiang, Hua-liang, Zhang, Wen-hong, Wang, Zhen, Liu, Gang-yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924727/ https://www.ncbi.nlm.nih.gov/pubmed/35296780 http://dx.doi.org/10.1038/s41401-022-00895-6 |
Ejemplares similares
-
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022) -
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
por: Xie, Yuanchao, et al.
Publicado: (2021) -
Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS
por: Zhou, Ainan, et al.
Publicado: (2023) -
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022) -
Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model
por: Zhang, Ruxue, et al.
Publicado: (2022)